2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Genomics, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

1989 One-step single-molecule countable PCR enables cis/trans phasing of BCR-ABL1 compound mutations in TKI-resistant CML

Yulei Shang, Ph.D, Vladyslava Ratushna, Ph.D2, Kelly Li, Ph.D3, Christina Fan, Ph.D4
1 Countable Labs, Palo Alto, California, United States
2 Countable Labs, Palo Alto, California, United States
3 Countable Labs, Palo Alto, California, United States
4 Countable Labs, Palo Alto, California, United States

Background:  Resistance to tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is frequently mediated by BCR-ABL1 kinase domain (KD) mutations, among which T315I and the P-loop mutations E255K/V are most prevalent. Co-occurrence of T315I with an E255 mutation carries direct therapeutic implications that depend on allelic configuration: compound mutations (in cis, same BCR-ABL1 molecule), such as E255K/T315I and E255V/T315I, confer resistance to all approved TKIs, including ponatinib, and warrant combination TKI therapy or allogeneic hematopoietic stem cell transplantation, whereas the same mutation pairs arising on independent clones (in trans) remain sensitive to ponatinib monotherapy. Determining this cis/trans relationship, and not mutation identity alone, is therefore essential to second-line therapy selection, yet no dedicated phasing assay exists in routine practice: only long-read sequencing resolves allelic configuration directly, and its reliance on sample send-out, extended turnaround, and specialized bioinformatics limits routine use. Here, we present a one-step PCR-based solution, using single-molecule amplification and linkage analysis, that determines phase directly without sequencing.

Methods: We developed a one-step multiplex RNA assay for targeting three clinically significant KD mutations (E255V, E255K, T315I), with ABL1 as the reference target. The assay was performed with Countable PCR, a single-molecule PCR technique that enables independent reverse transcription and amplification up to ~1 million single RNA molecules in a 50 µL reaction. The 6-log dynamic range of single-molecule counting and analysis resolves the cis vs. trans relationship of variants at E255 and T315 on BCR-ABL1 transcript, without the ambiguity associated with digital PCR because of restricted dynamic range and the complication of multi-molecule occupancy. The entire workflow, from sample partitioning, reverse-transcription PCR (RT-PCR) through counting on a dedicated benchtop imaging instrument, proceeds in a reaction tube without sample transfer and without bioinformatics analysis.

Results: In vitro transcribed RNA carrying various combinations of E255 (wild type or V/K) and T315 (wild type or I), were spiked into HL-60, at defined ratios across a dilution series. The assay accurately detects as few as ~10 mutant molecules of each cis/trans combination of E255 and T315, against a background of ~1×10⁶ ABL1 transcript molecules, achieving both highly sensitive and specific mutation-detection, as well as phasing within a single reaction. Low variance (coefficient of variation [CV] <10%) was maintained down to low variant allele fractions.

Conclusions: This single molecule counting and phasing assay enables sensitive, multiplexed detection of clinically actionable TKI resistance mutations without the turnaround time or bioinformatic burden of long-read NGS. This PCR-based phasing approach opens up a new modality for resolving cis/trans ambiguity of compound resistance mutations, to facilitate better clinical decision making for treatment. The approach can be extended to other use cases of compound mutations in which knowing the phases matter for clinical outcome.

 

Christina Fan, Ph.D: Countable Labs - Current equity holder in private company; Countable Labs - Current equity holder in private company; Countable Labs - Current Employment; Countable Labs - Current Employment